MONDAY, Aug. 11 (HealthDay News) -- Drugs known as
bisphosphonates, commonly prescribed to treat the bone-weakening
disease osteoporosis, don't appear to reduce the risk of breast
cancer as previously thought, new research finds.
"We found that postmenopausal women who took a bisphosphonate for three or four years did not have a decreased risk in breast cancer," said study author Trisha Hue, an epidemiologist at the University of California, San Francisco.
When prior observational studies noted links between the drugs'
use and lower breast cancer risk in, experts assumed the drugs
deserved the credit. However, based on the new findings, Hue
suspects that low estrogen levels may have been the
"Women who get bisphosphonates have a low bone mass density," she said. "If you have low bone mass density, you probably have low estrogen." This is because the hormone, which is depleted after menopause, helps regulate bone mass and strength. Many types of breast cancer need estrogen to grow, she said.
The study is published Aug. 11 in
JAMA Internal Medicine.
Previous studies that found the fringe benefit of reduced breast
cancer risk were observational, meaning people taking the drugs
happened to have lower breast cancer risk. But the research didn't
establish a direct cause-and-effect relationship.
Hue's team decided to take a look at two randomized clinical
trials that compared two popular osteoporosis drugs, Fosamax and
Reclast, to see if the women taking the drugs were less likely to
get breast cancer than women given a placebo, or sham drug.
In one study, nearly 6,500 women aged 55 to 81 were assigned to
take either Fosamax (alendronate) or a placebo. After about four
years, similar numbers of women got breast cancer -- 1.8 percent of
those on the drug and 1.5 percent of those on placebo.
The second study compared more than 7,700 women, aged 65 to 89,
given Reclast (zoledronic acid) intravenously or a placebo IV
infusion once a year. After nearly three years of follow-up, less
than 1 percent of women in each group developed breast cancer.
One expert said the results underscore the importance of
randomized clinical trials in demonstrating cause-and-effect.
"In this case, two randomized studies have disproved the notion that bisphosphonates reduce the risk of beast cancer, a finding that was supported by observational studies," said Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City.
Both types of studies are important, explained Dr. Jill Maura
Rabin, a professor of obstetrics and gynecology at Hofstra North
Shore-LIJ School of Medicine in New York.
While the new analysis suggests the drugs don't protect against
breast cancer, Rabin said follow-up for longer than three or four
years might still have found a benefit since breast cancer can take
years to develop.
Even so, the new research simply suggests that women prescribed
the drugs for bone health should continue taking them, Rabin said,
but just not expect a bonus of lower breast cancer risk.
To learn more about bone health, visit the
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.